Summary
Abbott Laboratories announced on October 11, 2019, that its Board of Directors has authorized a new share repurchase program of up to $3 billion of the company's common shares. This significant capital return initiative underscores the company's confidence in its financial health and its commitment to enhancing shareholder value. The new authorization is incremental to the existing $795 million remaining under a previous repurchase program initiated in September 2014. The company intends to execute these repurchases opportunistically, considering market conditions and regulatory requirements, signaling a flexible approach to managing its capital structure.
Key Highlights
- 1Abbott's Board of Directors authorized a new $3 billion share repurchase program.
- 2The new authorization demonstrates confidence in the company's financial stability and prospects.
- 3This program aims to return capital to shareholders and enhance shareholder value.
- 4The $3 billion is in addition to an existing $795 million unused repurchase authorization.
- 5Repurchases will be executed opportunistically based on market conditions and regulatory considerations.
- 6The repurchases may be made from time to time over an unspecified period.